Medical Findings in Infants Prenatally Identified with Sex 1 2 **Chromosome Trisomy in Year One of Life** 3 Nicole Tartaglia^{ab}, Shanlee Davis^{ab}, Susan Howell^{ab}, Samantha 4 Bothwell^{ab}, Kayla Nocon^{ab}, Karen Kowal^c Chijioke Ikomi^c, Andrew 5 Keene^{ab}, Victoria Reynolds^c, Agnethe Berglund^d, Judith Ross^c 6 7 8 **Affiliations:** ^aDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA; beXtraordinarY Kids Program, Children's Hospital Colorado, Aurora, Colorado, 9 USA; ^cNemours Children's Hospital, Wilmington, DE, USA; and ^dDepartment of Clinical 10 Genetics, Aarhus University Hospital, Aarhus, Denmark 11 12 Address correspondence to: Nicole Tartaglia, MD, Developmental Pediatrics, 13123 East 16th 13 Ave, B140, 720-777-6630, nicole.tartaglia@cuanschutz.edu 14 15 16 **Short title:** Medical Findings in Infants with Sex Chromosome Trisomy 17 Conflict of Interest Disclosures (includes financial disclosures): The authors have no conflicts 18 19 of interest to disclose. 20 21 Funding/Support: All phases of this study were supported by NIH/NICHD R01HD091251, NIH/NICHD K23HD092588, NIH/NCATS Colorado CTSA Grant Number UL1 TR002535. 22 23 24 Role of Funder/Sponsor: The NIH had no role in the design and conduct of the study. Contents are the authors' sole responsibility and do not necessarily represent official NIH views. 25 26 27 Clinical Trial Registration and Data Sharing Statement (if any): This study is registered on ClinicalTrials.gov NCT03396562 https://clinicaltrials.gov/study/NCT03396562. Data sharing is 28 29 available through requests from NICHD DASH (https://dash.nichd.nih.gov/) and includes 30 deidentified individual participant data, study protocols, DASH data codebook, and the informed 31 consent form. The data will be made available to researchers who provide methodologically sound proposals approved by the NICHD DASH Data or Biospecimen Access Committee. 32 33 **Abbreviations:** AGA: Average for gestational age; AMA: Advanced maternal age; ASD: Atrial 34 35 septal defect; BW: Birth weight; BL: Birth length; CDC: Centers for Disease Control; COMIRB: Colorado Multiple Institutional Review Board; CVS: Chorionic villus sampling; GU: 36 37 Genitourinary; LGA: Large for gestational age NICU: Neonatal Intensive Care Unit; PE: Pressure equalizing; SCT: Sex chromosome trisomies; SGA: Small for gestational age, VSD: 38 39 Ventricular septal defect 40 41 **Article Summary** Medical findings in largest cohort of prenatally identified infants with XXY, Trisomy X, and 42 XYY from birth to 12 months and implications for pediatric care. 43 44 What's Known on This Subject: 45

One in ~500 individuals have an extra X or Y chromosome, or sex chromosome trisomy (SCT). Prenatal screening is now routinely identifying SCT, however there are few studies to guide perinatal and infant care for these individuals.

What This Study Adds:

This prospective observational study presents medical features for 327 infants with prenatally identified SCT from birth through the first year of life. Results identify where proactive screenings and/or interventions may be warranted for infants with SCT.

86 87 88

89

90 91 92

93

94 95

96 97 98

99

100 101

102

103104

105

106107

108

109 110 111 **Contributors Statement Page** Drs. Nicole Tartaglia and Shanlee Davis conceptualized and designed the study, designed data collection instruments, supervised data collection, collected data, developed data analysis plan, drafted the initial manuscript, and critically reviewed and revised the manuscript. Dr. Judith Ross conceptualized and designed the study, supervised data collection, collected data, and critically reviewed and revised the manuscript. Dr. Chijioke Ikomi, Dr. Agnethe Berglund, Susan Howell and Karen Kowal collected data and critically reviewed and revised the manuscript. Samantha Bothwell conducted data analysis, generated tables and figures, and critically reviewed and revised the manuscript. Kayla Nocon and Victoria Reynolds participated in participant recruitment, study visit coordination, data collection and management, and critically reviewed and revised the manuscript. Andrew Keene participated in data collection, data sharing, manuscript preparation, and critically reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

112 113 **ABSTRACT:** 114 BACKGROUND AND OBJECTIVE: 115 116 Sex chromosome trisomies (SCT), including XXY, XYY, and XXX syndromes, have been historically underdiagnosed. Noninvasive prenatal cell-free DNA screening has significantly 117 increased identification of these conditions, leading to a need for pediatric care for a growing 118 population of newborns with SCT. Our goal was to analyze and compare perinatal features, 119 medical diagnoses, and physical features in infants with prenatal identification of SCT conditions 120 through the first year of life. 121 122 123 **METHODS:** The eXtraordinarY Babies Study is an ongoing, prospective natural history study of prenatally 124 identified children with SCT conducted by interdisciplinary teams in Colorado and Delaware. 125 Participants were enrolled prior to 12 months of age and had pregnancy, birth, medical histories, 126 and physical exams completed by board-certified pediatricians at 2, 6, and/or 12-month visits. 127 128 Descriptive statistics were followed by comparisons between SCT groups using t-tests or ANOVA, Fisher exact, and correlations between medical features with alpha of 0.05. Relative 129 risks were calculated compared to general population rates. 130 131 **RESULTS:** 132 327 infants were included in the analysis (XXY=195, XXX=79, XYY=53). Major congenital 133 anomalies were rare (1.7%). Relative risk compared to general population was elevated for 134 breastfeeding difficulties (51.7%; RR 2.7), positional torticollis (28.2%; RR 7.2), eczema 135 (48.0%; RR 3.5), food allergies (19.3%; RR 2.4), constipation requiring intervention (33.9%; RR 136 7.6), small cardiac septal defects (7.7%;RR 17.2), and structural renal abnormalities (4.4%;RR 137 9.7). Inpatient hospitalization was required for 12.4%, with 59.5% of hospitalizations attributable 138 to respiratory infections. 139 140 **DISCUSSION:** 141 These findings of medical conditions with a higher prevalence can inform anticipatory guidance 142 and medical management for pediatricians caring for infants with SCT. 143 144

KEYWORDS: XXY, Klinefelter syndrome, XYY, XXX, sex chromosome aneuploidy, infant

145

146147

INTRODUCTION:

Sex chromosome trisomies (SCT) occur in approximately 1:500 births and include XXY (Klinefelter syndrome) and XYY syndrome in males, and XXX (Trisomy X) syndrome in females. ^{1,2} Historically, prenatal diagnosis of SCT occurred only when chorionic villi sampling (CVS) or amniocentesis was indicated, such as due to abnormal ultrasound findings or advanced maternal age, accounting for only 5-10% of all cases of SCT. ³ An additional 5-25% were diagnosed postnatally upon presentation of clinical symptoms, however 65-90% of SCT cases remained undiagnosed. ³ The adoption of cell-free DNA (cfDNA) screening into routine prenatal care in the US has led to a marked increase in the prenatal identification of SCT, ⁴ resulting in a large cohort of infants with a known diagnosis. With a median of over 4,000 visits annually per pediatric physician, ⁵ each pediatrician will have several patients with SCT in their practice.

Due to the previously low rate of diagnosis in the prenatal period, there is a paucity of research on medical features in the early years of life. Prior international newborn screening studies identified 200 infants with SCT in the 1960's. These reports suggest that most infants with SCT are born at term and are not at an increased risk of congenital malformations or medical conditions during the neonatal period. ^{6,7} In childhood, tall stature and mild hypotonia are commonly described in the literature, as well as reports of atopic conditions, autoimmunity, constipation, seizure disorders, tremor, and recurrent respiratory infections. ⁷⁻¹² However, the preexisting literature relies on small sample sizes and selection bias, and therefore may not be generalizable to the population identified through prenatal cfDNA screening. Furthermore, while the medical complexity of these children is often assumed to be low, there is no information on healthcare utilization, such as hospitalization or surgery. Prevalence data for medical

comorbidities collected prospectively are needed to guide best care practices for pediatric SCT care and provide appropriate counseling to parents.

The surge of infants with SCT being identified by prenatal cfDNA screening provides a rich opportunity for prospective study of these infants to inform the natural history of these conditions. The eXtraordinarY Babies Study collects comprehensive data on health and development for prenatally identified infants with SCT starting within the first year of life to better inform least-biased risk and guide counseling and care for these infants. The aim of this study is to describe the prospective physical and medical features in the perinatal period and first year of life for a large, prenatally ascertained cohort of infants with SCT, and to compare features between SCT conditions and to the general population estimates.

METHODS:

Parents of infants identified prenatally and subsequently confirmed to have SCT were invited to participate in an IRB-approved natural history study called the eXtraordinarY Babies Study at one of two sites in Colorado or Delaware (ClinicalTrials.gov NCT03396562; COMIRB 17-0118; Nemours IRB# 1151006). Comprehensive descriptions of study methodology including recruitment and assessment measures have been previously published and are summarized in Figure 1, and this report focuses on medical and physical features identified within the first year of life. ¹³ In brief, inclusion criteria include genetic testing by amniocentesis or postnatal cytogenetic testing confirming SCT with less than 20% mosaicism with a typical cell line, gestational age at or above 34 weeks at birth, and enrollment prior to 12 months of age. Following written informed consent, data were collected by medical providers using review of medical records and a standardized interview with the parent(s) developed for the study that

included detailed birth and medical histories. Study visits occurred at 2, 6, and/or 12-months of age depending on timing of enrollment, and visits were conducted in-person and/or via telehealth due to COVID-19 restrictions during the study period.

Demographic data were collected through a standardized parent survey, and 4 Factor Hollingshead Index was calculated as previously described. ¹⁴ Physical examination was conducted by board-certified pediatrician at 2, 6, and/or 12-month visits in person visits. Birthweight (BW) and length (BL) measurements were converted to z-scores for gestational age and sex according to US norms. ¹⁵ Descriptive metrics (proportions, means) and estimates (95% confidence intervals or standard deviations) for each outcome were calculated for the whole sample as well as stratified by SCT. Outcomes were compared between SCT groups using fisher's exact tests, for low cell counts, or ANOVA followed by pairwise comparisons. Finally, when rigorous published data were available for the general pediatric population, risk ratios and 95% confidence intervals were calculated by unconditional maximum likelihood estimation (Wald) in the epitools R package to determine whether the SCT sample proportion differed from what is expected in the general population. All analyses were two-sided with a type 1 error rate set at 0.05. Data were stored and managed in the secure REDCap database and all analyses were conducted in RStudio v2022.12.0 using R v.4.2.2.

RESULTS:

The full sample consisted of 327 infants (XXY n=195, XXX n=79, XYY n=53) representing 47 US states (Figure 2) and diverse racial and ethnic backgrounds (Table 1). Nearly all (95%) were initially identified to have SCT via prenatal cfDNA screening performed either for advanced maternal age or no clinical indication (elective), while the minority (~5%) had

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

abnormal ultrasound and/or biochemical markers prompting prenatal genetic testing (Table 2). All participants except for 3 females with XXX were non-mosaic; the 3 mosaic cases were 47,XXX/46,XX with <20% 46,XX cell line in all cases. Pregnancies were largely uncomplicated, and the vast majority of the cohort was born full-term via vaginal delivery at a mean gestational age 38.7±1.5 weeks. Most infants (85.2%) were average-for-gestational age (AGA), however, infants with XXY and XXX had lower mean weight and length z-scores at birth than those with XYY. Major congenital anomalies were identified in 1.7% of the cohort, including hypospadias (n=3, all subcoronal), cleft lip/palate (n=1), and clubfoot (n=1), which is not different from general population estimates (up to 3% ¹⁶) (Table 3). Common minor congenital anomalies (Figure 3) were fifth digit clinodactyly (49.0%), epicanthal folds (45.1%), torticollis (28.2%), plagiocephaly (18.8%), umbilical hernia (9.1%), and preauricular tags (6.3%). Overall mean zscore for intercanthal distance was nearly a full standard deviation higher than norms (z-score – 0.94 (95% CI: -1.37, 2.79), however only 2.7% met criteria for hypertelorism (z-score > 2.0). There were very few differences in the rates of physical findings between SCT groups. Males with XXY had lower stretched penile length compared to XYY at 2 months (p<0.001), however mean length in the XXY group was only a quarter of a standard deviation below the mean for the general population, and only 8 (5.4%) met criteria for short penis length (stretch penile length zscore <-2.0) in those with a study exam who had not received testosterone treatment (Table 4). Study protocol did not include standard imaging, however of those who had clinical postnatal echocardiograms completed (n=109), cardiac septal defects (atrial and/or ventricular) were found in 23 (21.1%), which is 7.7% of the cohort overall. None of the infants with identified ASD or VSD required invasive cardiac procedures within the first year of life,

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

however one infant required surgery for a symptomatic vascular ring secondary to double aortic arch. Of the 78 infants who had a clinical renal ultrasound, 13 (16.7%) had a structural abnormality, which represents 4.4% of the full cohort (vs 0.45% in the general population, ¹⁷ p<0.001). When stratified by karyotype, girls with XXX were more likely to have received an echocardiogram and/or renal ultrasound, however the proportion with abnormal findings of those who had imaging did not significantly differ between SCT subtypes. Breastfeeding difficulties occurred in half of the cohort and equally between the three SCT conditions, predominantly due to difficulties with latch and/or inadequate milk transfer. Despite this, the mean duration of breastmilk feeding was 8.0±5.5 months with 61.1% of infants still receiving breastmilk at 6 months and 43.3% at 12 months, both at or above US national statistics (58.2% and 37.6%, respectively). ¹⁸ The presence of breastfeeding difficulties was associated with receiving a frenotomy (21.7% vs 4.8%, p<0.001), earlier age of formula introduction (3.6 \pm 3.5 vs 4.7 \pm 3.5 months, p=0.013), as well as a diagnosis of failure to thrive (28.0% vs 11.9%, p=0.002). There was no relationship with breastfeeding difficulties and hypotonia, micrognathia, high arched palate, reflux, or constipation (p>0.05 for all). Constipation was more common in all SCT groups compared to the general population (33.9% vs 7.0%, p<0.001) ¹⁹ and was associated with hypotonia (p<0.001). Atopic conditions were present in 54.7% of all infants within the first year of life. Eczema was present in 48.0% of all infants with SCT vs 13.7% in general population (RR 3.5 [3.1-3.9], p<0.001) ²⁰ and allergies (food, environmental, and/or medication) were present in 24.2% vs 10.4% in the general population (RR 2.6 [2.1-3.2], p<0.001)²¹. The risk of food allergies was 2.4 times greater in infants with SCT compared to general population estimates $(19.3\% \text{ vs } 8\%, 95\% \text{ CI } 1.9-3.1, p<0.001)^{22}$, with a mean age of 5.8 ± 4.0 months at diagnosis.

Food allergies were more common among infants with eczema (28.7% vs 11.0%, p=0.001) and reflux (31.6% vs 13.7%, p<0.001).

Acute infectious diagnoses including otitis media (21.1%), bronchiolitis (12.8%) and pneumonia (2.7%) were similar to estimates in the general population. Overall, 12.4% of the cohort required inpatient hospitalization within the first year of life, with 59.5% of these hospitalizations attributable to respiratory etiologies. Surgeries occurred in 10.7% of the cohort, with the most common indication being for repair of minor GU anomalies.

Weight and weight-for-length z-scores increase in the first year of life for all SCTs, while length z-scores increase from birth to the first year of age for boys but not XXX (Table 4 and Figure S1). By 12 months of age, growth parameters in all 3 groups were within 1 standard deviation of the mean for the general population.

DISCUSSION:

This large, prospective cohort study describes the comprehensive natural history of prenatal, birth, physical findings and medical conditions arising within the first year of life for infants prenatally identified to have SCT. Overall, major congenital anomalies and complex medical conditions were uncommon and there were minimal differences in perinatal and infant findings between SCT groups. We observed several findings warranting clinical consideration within the first year of life, including breastfeeding problems, failure to thrive, torticollis, constipation, structural cardiac and renal differences and atopic conditions (Table 5). The results from this study directly inform pediatric care as providers and families can be reassured that a prenatal diagnosis of SCT is not associated with complex medical or physical abnormalities within the first year of life, but proactive monitoring for select at-risk conditions is warranted.

Our results support that pregnancies affected by SCT are generally healthy and neither fetal nor maternal complications are obviously different from the general population. Based on these observations, standard prenatal care is appropriate, aside from genetic counseling and decisions on timing of diagnostic genetic testing. ²³ However, as conditions requiring medical interventions occurred in approximately 1 out of 4 neonates in our cohort, we recommend that delivery is planned at a facility equipped to manage potential neonatal complications including hypoglycemia, hyperbilirubinemia requiring phototherapy, and respiratory insufficiency. Furthermore, our observed prevalence of transient neonatal hypoglycemia may be an underestimates as most term, AGA infants are not routinely evaluated for hypoglycemia and neonatal hypoglycemia often does not present with overt symptoms. ²⁴ Therefore, neonates with SCT may benefit from routine glucose screening and additional research.

While major congenital malformations were rare, structural cardiac and renal anomalies occurred more commonly than expected and this prevalence is likely underestimated given the minority of participants had echocardiograms or renal imaging. Indications for echocardiogram or renal imaging varied, with some being performed as general screening due to a known chromosomal abnormality and others due to prenatal concern or postnatal exam findings such as murmur. Congenital cardiac and renal anomalies have been previously associated with XXX, ²⁵ but these conditions in males with SCT are primarily limited to case reports. ²⁶⁻³⁰ The high prevalence of abnormal imaging among all infants with SCTs supports universal postnatal screening with echocardiogram and renal ultrasound to identify anatomical defects, however it is also important to acknowledge that none of the individuals required intervention within the first year of life unless symptoms were present. Longitudinal follow up and additional studies are

needed to confirm whether structural cardiac and renal imaging findings in SCTs have clinical implications warranting universal imaging in asymptomatic individuals.

Interestingly, in males with XXY, structural cardiac and renal defects were just as common as genital abnormalities which traditionally have been more commonly associated with XXY. While cumulatively ~10% of the XXY cohort did have minor genitourinary differences which have previously been attributed to testosterone differences in XXY, penile structural abnormalities (hypospadias and chordee) were also observed in 4.4% of males with XYY, suggesting a possible etiology associated with the additional sex chromosome rather than a hormonal etiology. Regarding penile size, true micropenis on our examination was rare, with mean penile length z-score in XXY of -0.3 in those not treated with testosterone. This is important as there is common belief that XXY is associated with short penile length. While a thorough GU examination is advised, most babies will have typical genitalia. Subsequent analyses will evaluate serum hormone concentrations and relationship to health, physical, and developmental outcomes.

Despite a highly motivated study sample with >90% attempting breastfeeding, breastfeeding difficulties were present in over half of the sample and associated with inadequate growth for a subset in the first months of life. We did not systemically evaluate quality of breastfeeding, reasons for breastfeeding challenges, or ankyloglossia which warrant further study. We noted a high rate of frenotomy procedures with differences between karyotypes (29% in XYY). Ankyloglossia occurs in ~7% of infants in the general population³¹ and is a known cause of breastfeeding difficulties. Further, frenotomy can be beneficial if ankyloglossia is present. ³²⁻³³ The high rate of frenotomy observed in our cohort highlights the need for additional research to identify the true prevalence and classifications of ankyloglossia in infants with SCT,

breastfeeding. Breastfeeding challenges may reflect neurodevelopmental delays in oral-motor planning and coordination, congruent with previous studies that have identified oral-motor dyspraxia in SCTs. ³⁴⁻³⁷ Other anatomical differences (such as micrognathia or high-arched palate), ³⁸ low muscle tone, or poor endurance could also theoretically contribute to feeding difficulties, however we did not observe a relationship with these features and feeding problems in our cohort. The relationship of early feeding problems with later developmental outcomes will be explored in future analyses as the cohort ages. From a clinical perspective, proactive support with lactation consultation may be beneficial, and it is important to appreciate that many infants with SCT were able to receive breastmilk for a similar duration as the general population, either through adequate lactation support and/or expressed breastmilk. Studies of the etiology of breastfeeding problems and specific interventions to support successful breastfeeding in this population are needed.

The prevalence of atopic conditions was one of the most striking medical findings occurring in the first year, with nearly half having eczema and 1 in 5 with a food allergy. This association has been previously reported in SCTs, although we did not expect to find this high of prevalence within the first year of life. While we did not systematically capture disease severity, anecdotally eczema was rarely severe and improved with age. Nevertheless, these findings suggest an altered immune system response in infants with SCT that warrants additional investigation.

We acknowledge limitations of the study, including sample size discrepancies between SCT groups, subjectivity of some of the outcomes, and reliance on published reference data for comparison to the general population. Overestimation of some findings may occur given a

diagnosis of a genetic condition may introduce bias to search for and potentially identify abnormalities. It is also possible that our study underestimates the true prevalence of congenital anomalies in SCTs as our study does not include fetuses that may have been spontaneously or electively terminated. Recognizing these limitations, this study contributes vital statistics describing early phenotypic features in SCTs and has important counseling and clinical management implications.

As this cohort ages through the toddler and school-aged years, comprehensive prospective data collection will allow for broader descriptions on the natural history of medical features into childhood. Ongoing recruitment priorities include increased racial, ethnic, and socioeconomic diversity of the study cohort and more balanced sample sizes between the three SCT conditions. Analyses exploring the relationships of family medical history, neurodevelopmental outcomes, reproductive hormone concentrations, and other systemic biomarkers may identify specific predictors or subpopulations most at risk for poorer health outcomes that would guide more intensive early supports, therapies, and medical follow-up.

As prenatal cfDNA screening is now routinely identifying SCT conditions and more infants are presenting to primary care providers with a prenatal diagnosis, there is an acute need for contemporary evidence on perinatal and infant comorbidities to guide counseling and care. Our results support that counselors and medical providers can reassure families that most infants have a typical perinatal course, and that most medical conditions that arise are common in the general pediatric population, well-known to pediatric providers, and respond to evidence-based interventions. For those medical conditions that are indeed more common and cause challenges in the first year of life, anticipatory guidance and close monitoring can facilitate appropriate interventions and timely support.

ACKNOWLEDGEMENTS

We would like to acknowledge additional team members contributing to this study including previous research coordinators Amira Herstik, Tanea Tanda, Sierra Kaiser, Caroline Harrison, Jillian Kirk, Mariah Brown, Amanda Alstrom, Gabrielle Stefy, and Julia Jaen. We would like to thank AXYS (www.genetic.org), Living with XXY, and the Colorado Genetic Counseling Symposium, for support in recruitment and study dissemination, the ACMG Newborn Screening Translational Research Network team for support with database design and data sharing.

REFERENCES

- 1. Nielsen J. Sex Chromosome Abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. *Birth Defects Orig Artic Ser*. 1990;26(4):209-23.
- 2. Morris JK, Alberman E, Scott C, Jacobs P. Is the prevalence of Klinefelter syndrome increasing? *Eur J Hum Genet*. Feb 2008;16(2):163-70. doi:10.1038/sj.ejhg.5201956
- 3. Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. *J Clin Endocrinol Metab*. Feb 2003;88(2):622-6.
- 4. Loughry L, Pynaker C, White M, Halliday J, Hui L. State-wide increase in prenatal diagnosis of klinefelter syndrome on amniocentesis and chorionic villus sampling: Impact of non-invasive prenatal testing for sex chromosome conditions. *Prenat Diagn*. Feb 2023;43(2):156-161.
- 5. Pediatrics AAo. *Socioeconomic Survey of Pediatric Practices*. American Academy of Pediatrics; 2009.
- 6. Robinson A. Studies on infants and children with sex chromosomal abnormalities. *Advances in pathobiology.* 1977;(6):214-26.
- 7. Robinson A, Bender BG, Linden MG. Summary of clinical findings in children and young adults with sex chromosome anomalies. *Birth Defects Orig Artic Ser*. 1990;26(4):225-8.
- 8. Liu K, Kurien BT, Zimmerman SL, et al. X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. *Arthritis Rheumatol*. 05 2016;68(5):1290-1300.
- 9. Panimolle F, Tiberti C, Spaziani M, et al. Non-organ-specific autoimmunity in adult 47,XXY Klinefelter patients and higher-grade X-chromosome aneuploidies. *Clin Exp Immunol*. Sep 2021;205(3):316-325.
- 10. Borodyanskya M, Tartaglia N, Davis S, Hagerman R. Tremor in Children with Sex Chromosome Aneuploidy. *Journal of Investigative Medicine*. 2007;55(1):S247.
- 11. Wigby K, D'Epagnier C, Howell S, et al. Expanding the phenotype of Triple X syndrome: A comparison of Prenatal versus Postnatal Diagnosis. *American Journal of Medical Genetics Part A*. 2016;170(11):2870-2881.

- 12. Bojesen A, Juul S, Birkebaek NH, Gravholt CH. Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. *J Clin Endocrinol Metab*. Apr 2006;91(4):1254-60.
- 13. Tartaglia N, Howell S, Davis S, et al. Early neurodevelopmental and medical profile in children with sex chromosome trisomies: Background for the prospective eXtraordinarY babies study to identify early risk factors and targets for intervention. *Am J Med Genet C Semin Med Genet*. Jun 2020;184(2):428-443.
- 14. Hollingshead A. *Four Factor Index of Social Status*. Yale University Department of Psychology; 1975.
- 15. Olsen IE, Groveman SA, Lawson ML, Clark RH, Zemel BS. New intrauterine growth curves based on United States data. *Pediatrics*. Feb 2010;125(2):e214-24.
- 16. Egbe AC. Birth defects in the newborn population: race and ethnicity. *Pediatr Neonatol*. Jun 2015;56(3):183-8.
- 17. Egbe A, Uppu S, Lee S, Stroustrup A, Ho D, Srivastava S. Congenital malformations in the newborn population: a population study and analysis of the effect of sex and prematurity. *Pediatr Neonatol*. Feb 2015;56(1):25-30.
- 18. Centers for Disease Control, National Center for Immunizations and Respiratory Diseases, Breastfeeding Facts, 2021-2022 National Immunization Survey Child, 2023.
- 19. Loening-Baucke V. Prevalence, symptoms and outcome of constipation in infants and toddlers. *J Pediatr*. Mar 2005;146(3):359-63.
- 20. Choragudi S, Yosipovitch G. Trends in the Prevalence of Eczema Among US Children by Age, Sex, Race, and Ethnicity From 1997 to 2018. *JAMA Dermatol*. 2023 Apr 1;159(4):454-456.
- 21. Zablotsky B, Black LI, Akinbami LJ. Diagnosed Allergic Conditions in Children Aged 0-17 Years: United States, 2021. *NCHS Data Brief*. Jan 2023;(459):1-8.
- 22. Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. *Pediatrics*. Jul 2011;128(1):e9-17.
- 23. Howell S, Davis SM, Thompson T, Brown M, Tanda T, Kowal K, Alston A, Ross J, Tartaglia NR. Noninvasive prenatal screening (NIPS) results for participants of the eXtraordinarY babies study: Screening, counseling, diagnosis, and discordance. J Genet Couns. 2023 Feb;32(1):250-259.
- 24. Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. *J Pediatr*. Aug 2015;167(2):238-45.
- 25. Wigby K, D'Epagnier C, Howell S, et al. Expanding the phenotype of Triple X syndrome: A comparison of prenatal versus postnatal diagnosis. *American journal of medical genetics Part A*. Nov 2016;170(11):2870-2881.
- 26. Peng R, Zheng J, Xie HN, He M, Lin MF. Genetic anomalies in fetuses with tetralogy of Fallot by using high-definition chromosomal microarray analysis. *Cardiovasc Ultrasound*. May 06 2019;17(1):8.
- 27. Rudnik-Schöneborn S, Schüler HM, Schwanitz G, Hansmann M, Zerres K. Further arguments for non-fortuitous association of Potter sequence with XYY males. *Ann Genet*. 1996;39(1):43-6.
- 28. Barroeta JE, Stopyra GA. 47,XXY with associated bilateral renal agenesis. *Arch Pathol Lab Med.* Mar 2004;128(3):e44-5.

- 29. Nwosu BU, Hopkins TB. Newborn with Klinefelter syndrome and posterior urethral valves. *Urology*. Nov 2008;72(5):1033-5
- 30. Rao VS, Mooring PK. Ebstein's anomaly in XXY Klinefelter's syndrome. *Am J Dis Child*. Aug 1970;120(2):164-5.
- 31. Cruz PV, Souza-Oliveira AC, Notaro SQ, et al. Prevalence of ankyloglossia according to different assessment tools: A meta-analysis. *J Am Dent Assoc*. Nov 2022;153(11):1026-1040.e31.
- 32. O'Shea JE, Foster JP, O'Donnell CP, et al. Frenotomy for tongue-tie in newborn infants. *Cochrane Database Syst Rev.* Mar 11 2017;3(3):CD011065.
- 33. Cordray H, Raol N, Mahendran GN, et al. Quantitative impact of frenotomy on breastfeeding: a systematic review and meta-analysis. *Pediatr Res.* Jan 2024;95(1):34-42
- 34. Salbenblatt J, Meyers DC, Bender B, Linden MG, Robinson A. Gross and fine motor development in 47,XXY and 47,XYY males. *Pediatrics*. 1987;80(240-244)
- 35. Salbenblatt JA, Meyers DC, Bender BG, Linden MG, Robinson A. Gross and fine motor development in 45,X and 47,XXX girls. *Pediatrics*. Oct 1989;84(4):678-82.
- 36. Samango-Sprouse C, Rogol A. XXY The Hidden Disability and a Prototype for an Infantile Presentation of Developmental Dyspraxia (IDD). *Infants and Young Children*. 2002;15(1):11-18.
- 37. Martin S, Cordeiro L, Richardson P, Davis S, Tartaglia N. The Association of Motor Skills and Adaptive Functioning in XXY/Klinefelter and XXYY Syndromes. *Phys Occup Ther Pediatr*. 2019;39(4):446-459.
- 38. Close S, Fennoy I, Smaldone A, Reame N. Phenotype and Adverse Quality of Life in Boys with Klinefelter Syndrome. *J Pediatr*. Sep 2015;167(3):650-7.
- 39. Gianni ML, Bettinelli ME, Manfra P, et al. Breastfeeding Difficulties and Risk for Early Breastfeeding Cessation. *Nutrients*. 2019 Sep 20; 11(10):2266.
- 40. Daniel M, Kleis L, Cemeroglu AP. Etiology of failure to thrive in infants and toddlers referred to a pediatric endocrinology outpatient clinic. *Clin Pediatr (Phila)*. Oct 2008;47(8):762-5.
- 41. Barberio B, Judge C, Savarino EV, Ford AC. Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. Aug 2021;6(8):638-648.
- 42. Sood MR. Chronic functional constipation and fecal incontinence in infants, children, and adolescents: Treatment. In: Li BUK, ed. *UpToDate*. Wolters Kluwer; 2024.
- 43. Gupta RS, Warren CM, Smith BM, et al. The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States. *Pediatrics*. 2018;142(6):e20181235.
- 44. Choragudi S, Yosipovitch G. Trends in the Prevalence of Eczema Among US Children by Age, Sex, Race, and Ethnicity From 1997 to 2018. *JAMA Dermatol*. Apr 1 2023;159(4):454-456.
- 45. Chen MM, Chang HC, Hsieh CF, Yen MF, Chen TH. Predictive model for congenital muscular torticollis: analysis of 1021 infants with sonography. *Arch Phys Med Rehabil*. Nov 2005;86(11):2199-203.
- 46. Aarnivala HE, Valkama AM, Pirttiniemi PM. Cranial shape, size and cervical motion in normal newborns. *Early Hum Dev.* Aug 2014;90(8):425-30.
- 47. Virtanen HE, Toppari J. Epidemiology and pathogenesis of cryptorchidism. *Hum Reprod Update*. Jan-Feb 2008;14(1):49-58.

- 48. Christopher SE, Meira SH, Jane P, Yvonne M, Linda DS. Epidemiologic trends in penile anomalies and hypospadias in the state of California, 1985–2006. *Journal of Pediatric Urology*. 2011;7(3):294-298.
- 49. Montag S, Palmer LS. Abnormalities of penile curvature: chordee and penile torsion. *ScientificWorldJournal*. Jul 28 2011;11:1470-8.
- 50. Pathai S, Cumberland PM, Rahi JS. Prevalence of and early-life influences on childhood strabismus: findings from the Millennium Cohort Study. *Arch Pediatr Adolesc Med.* Mar 2010;164(3):250-7.
- 51. Liu Y, Chen S, Zühlke L, et al. Global birth prevalence of congenital heart defects 1970-2017: updated systematic review and meta-analysis of 260 studies. *Int J Epidemiol*. Apr 1 2019;48(2):455-463.
- 52. Egbe A, Uppu S, Lee S, Stroustrup A, Ho D, Srivastava S. Congenital malformations in the newborn population: a population study and analysis of the effect of sex and prematurity. Pediatr Neonatol. Feb 2015;56(1):25-30.
- 53. Straathof EJM, Heineman KR, Hamer EG, Hadders-Algra M. Patterns of atypical muscle tone in the general infant population Prevalence and associations with perinatal risk and neurodevelopmental status. *Early Hum Dev.* Jan 2021;152:105276.

TABLE 1: Participant Demographics

					ANOVA or Fisher's Exact Test
	Overall	XXX	XXY	XYY	p-value
n	327	79	195	53	
Enrollment site (%)					0.741
Colorado	249 (76.1)	58 (73.4)	149 (76.4)	42 (79.2)	
Nemours	78 (23.9)	21 (26.6)	46 (23.6)	11 (20.8)	
Enrollment Age in Months Median (IQR)	4.6 (2.5, 7.6)	6.0 (3.1, 8.7)	3.0 (2.3, 7.0)	6.4 (3.3, 11.0)	
Enrollment Visit Window (%)					0.002*1
2 months	163 (49.8)	30 (38.0)	115 (59.0)	18 (34.0)	
6 months	90 (27.5)	30 (38.0)	40 (20.5)	20 (37.7)	
12 months	71 (21.7)	19 (24.1)	38 (19.5)	14 (26.4)	
Other	3 (0.9)	0	2 (1.0)	1 (1.9)	
Race (%)					0.364
Asian	10 (3.1)	4 (5.1)	6 (3.1)	0	
Black	9 (2.8)	1 (1.3)	5 (2.6)	3 (5.7)	
Other / More than one race	38 (11.6)	6 (7.6)	25 (12.8)	7 (13.2)	
White	270 (82.6)	68 (86.1)	159 (81.5)	43 (81.1)	
Ethnicity (%)					0.969
Hispanic/Latino	50 (15.3)	11 (13.9)	31 (15.9)	8 (15.1)	
Not Hispanic/Latino	277 (84.7)	68 (86.1)	164 (84.1)	45 (84.9)	
Hollingshead					0.368
4-factor Index mean (SD)	53.0 (9.8)	54.4 (7.8)	52.7 (10.4)	52.2 (10.3)	
Annual Household Income (%)					0.604
< \$75,000	43 (13.1)	8 (10.1)	25 (12.8)	10 (18.9)	
\$75,000-150,000	109 (33.3)	26 (32.9)	65 (33.3)	18 (34.0)	
\$150,000-250,000	85 (26.0)	26 (32.9)	48 (24.6)	11 (20.8)	
>\$250,000	88 (26.9)	18 (22.8)	56 (28.7)	14 (26.4)	
Did not report	2 (0.6)	1 (1.3)	1 (0.5)	0	
Underrepresented (%) ²	101 (30.9)	22 (27.8)	64 (32.8)	15 (28.3)	0.689
Region (US Census Bureau) (%)					0.336

ANOVA or Fisher's Exact Test

	Overall	XXX	XXY	XYY	p-value
International	7 (2.1)	0	3 (1.5)	4 (7.5)	
Midwest	47 (14.4)	12 (15.2)	30 (15.4)	5 (9.4)	
Northeast	68 (20.8)	16 (20.3)	39 (20)	13 (24.5)	
South	86 (26.3)	23 (29.1)	51 (26.2)	12 (22.6)	
West	119 (36.4)	28 (35.4)	72 (36.9)	19 (35.8)	

Categorical data are represented as n (%), and continuous data are mean (standard deviation)

^{*}p<0.05

¹ Pairwise comparison analysis: 2 month visit XXY > XXX, XYY

² Underrepresented includes non-White, Hispanic, and/or family income <\$50K USD/year

TABLE 2: Prenatal and Perinatal History

					ANOVA or Fisher's Exact
	Overall	XXX	XXY	XYY	p-value
n	327	79	195	53	
Initial Genetic Test					
Cell-free DNA Screening	315 (96.3)	75 (94.9)	188 (96.9)	51 (96.2)	0.651
CVS ¹ or Amniocentesis	35 (10.7)	6 (7.6)	20 (10.3)	9 (17)	0.247
Reason for Prenatal Test					0.595
Abnormal Ultrasound or Serum Test	15 (4.6)	6 (7.6)	6 (3.1)	3 (5.7)	
Advanced Maternal Age (AMA)	165 (50.5)	35 (44.3)	104 (53.3)	26 (49.1)	
Routine/Elective	127 (38.8)	33 (41.8)	74 (37.9)	20 (37.7)	
Other ²	20 (6.1)	5 (6.3)	11 (5.6)	4 (7.5)	
Parental Age at Birth					
Maternal age (yrs) mean (SD)	34.9 (4.9)	35.7 (4.9)	34.8 (5.0)	34.1 (4.6)	0.153
Paternal age (yrs) mean (SD)	36.7 (5.9)	37.4 (5.8)	36.3 (6.0)	36.9 (5.4)	0.316
Gestational Diabetes	29 (8.9)	11 (13.9)	15 (7.7)	3 (5.7)	0.215
Delivery Method					0.634
Cesarian section	109 (33.3)	28 (35.4)	61 (31.3)	20 (37.7)	
Gestational Age (weeks) mean (SD)	38.7 (1.4)	38.6 (1.5)	38.7 (1.4)	38.8 (1.4)	0.755
Gestational Age Category ³					0.607
Preterm (34-36 weeks)	27 (8.3)	5 (6.3)	16 (8.2)	6 (11.3)	
Full Term (≥37.0 weeks)	300 (91.7)	74 (93.7)	179 (91.8)	47 (88.7)	
Growth Parameters at Birth ⁴					
Birthweight (grams) mean (SD)	3230 (542)	3130 (544)	3210 (520)	3420 (580)	0.009*5
Birthweight Z-score mean (SD)	-0.25 (0.87)	-0.23 (0.91)	-0.33 (0.82)	0.04 (0.92)	0.022*5,6
Birth Length (cm) mean (SD)	50.4 (2.9)	49.5 (2.6)	50.5 (2.9)	51.5 (2.8)	<0.001*5
Birth Length Z-score mean (SD)	0.02 (0.95)	-0.12 (0.91)	-0.02 (0.96)	0.36 (0.91)	0.024*5,7
Birth Size Category					0.1086
Small for gestational age	35 (10.7)	6 (7.6)	26 (13.3)	3 (5.7)	
Average for gestational age	279 (85.3)	68 (86.1)	165 (84.6)	46 (86.8)	
Large for gestational age	12 (3.7)	4 (5.1)	4 (2.1)	4 (7.5)	

Neonatal Medical Course

ANOVA	or Fishe	er's Exact
	UI I ISIIC	л э пласі

	Overall	XXX	XXY	XYY	p-value
Intubation and/or Ventilation	15 (4.6)	5 (6.3)	7 (3.6)	3 (5.7)	0.452
Hyperbilirubinemia	47 (14.4)	9 (11.4)	29 (14.9)	9 (17.0)	0.655
Hypoglycemia	25 (7.6)	5 (6.3)	16 (8.2)	4 (7.5)	0.955
NICU Admission ⁸	35 (10.7)	11 (13.9)	19 (9.7)	5 (9.4)	0.586

Categorical data are represented as n (%), and continuous data are mean (standard deviation)

- 2 Other; other reasons include previous pregnancy with chromosome abnormality (n=6), IVF pregnancy (n=3), genetic disorder in family (n=5), previous high risk pregnancy (n=3), other pregnancy complication (n=3)
- 3 Study inclusion criteria required birth ≥ 34 weeks gestation
- 4 Based on Fenton gestational age growth curves
- 5 Pairwise comparisons analysis: XXY, XXX<XYY
- 6 Pairwise comparisons analysis: XXY<XXX, XYY
- 7 Pairwise comparisons analysis: XXX<XXY, XYY
- 8 NICU Admissions were for respiratory distress, hypoglycemia, and feeding difficulties

^{*}p<0.05

¹ CVS = Chorionic Villus Sampling

TABLE 3: Medical Problems from Birth to 12 months

n 298 71 182 45 Breastfeeding Problems 154 (51.7) 39 (54.9) 90 (49.5) 25 (55.6) 0.983 Aspiration 12 (4.0) 4 (5.6) 6 (3.3) 2 (4.4) 0.630 Allergies - Any 72 (24.2) 13 (18.3) 49 (26.9) 10 (22.2) 0.331 Food Allergy onset mean age (SD) 58 (40.9) 10 (14.1) 39 (21.4) 9 (20.0) 0.428 Food Allergy onset mean age (SD) 5.8 (40.0) 3.8 (2.7) 6.5 (4.1) 4.6 (3.8) 0.0894 Environmental/Seasonal Allergies 19 (6.4) 1 (1.4) 15 (8.2) 3 (6.7) 0.106 Environmental/Seasonal Allergies 19 (6.4) 9.0 (NA) 6.8 (3.8) 7.0 (1.0) 0.838 Medication Allergy age at onset mean (SD) 6.9 (3.4) 9.0 (NA) 6.8 (3.8) 7.0 (1.0) 0.838 Eczema 143 (48.0) 23 (2.4) 9.7 (5.3) 23 (5.1) 0.008** Eczema 143 (48.0) 23 (2.4) 9.7 (3.3) 23 (5.1) 0.063 Brock Lic		a 11			*****	Fisher's Exact
Preastfeeding Problems		Overall	XXX	XXY	XYY	p-value
Aspiration 12 (4.0) 4 (5.6) 6 (3.3) 2 (4.4) 0.630 Allergies - Any 72 (24.2) 13 (18.3) 49 (26.9) 10 (22.2) 0.331 Food Allergy onset mean age (SD) 58 (19.5) 10 (14.1) 39 (21.4) 46 (3.8) 0.0894 Environmental/Seasonal Allergies 19 (64) 1 (1.4) 15 (8.2) 3 (6.7) 0.106 Environmental/Seasonal age at onset mean (SD) 6.9 (3.4) 9.0 (NA) 6.8 (3.8) 7.0 (1.0) 0.838 Medication Allergy 6 (2.0) 3 (4.2) 3 (1.6) 0 0.356 Medication Allergy age at onset mean (SD) 10.5 (4.2) 11.3 (5.0) 9.7 (4.0) NA (NA) 0.678 Eczema 143 (48.0) 23 (3.2) 9.7 (5.3) 23 (5.1) 0.008*** Eczema 143 (48.0) 23 (3.2) 9.7 (5.3) 23 (5.1) 0.008*** Reactive Airway Disease 5 (1.7) 0 4 (2.2) 10 (22.2) 0.555 Ottis Media 38 (12.8) 6 (8.5) 23 (12.6) 9 (20.0) 0.24 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
Allergies - Any 72 (24.2) 13 (18.3) 49 (26.9) 10 (22.) 0.331 Food /Formula Allergies 58 (19.5) 10 (14.1) 39 (21.4) 9 (20.0) 0.428 Food Allergy onset mean age (SD) 58 (40.0) 3.8 (2.7) 6.5 (4.1) 4.6 (3.8) 0.0894 Environmental/Seasonal Allergies 19 (64.0) 9.0 (NA) 6.8 (3.8) 7.0 (1.0) 0.838 Medication Allergy 6 (2.0) 3 (4.2) 3 (1.6) 0 0.356 Medication Allergy age at onset mean (SD) 10.5 (4.2) 11.3 (5.0) 9.7 (4.0) NA (NA) 0.678 Eczema 143 (48.0) 23 (32.4) 97 (5.3) 23 (5.1) 0.08*** Reactive Airway Disease 5 (1.7) 0 4 (2.2) 1 (2.2) 0.555 Ottitis Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.555 Ottitis Media 8 (2.7) 1 (1.4) 7 (3.2) 0.02 0.20 Procuptioni 1 (3.2) 4 (8.5) 2 (12.6) 9 (20.0) 0.20	G				-	
Food/Formula Allergies 58 (19.5) 10 (14.1) 39 (21.4) 9 (20.0) 0.428 Food Allergy onset mean age (SD) 5.8 (4.0) 3.8 (2.7) 6.5 (4.1) 4.6 (3.8) 0.0894 Environmental/Seasonal Allergies 19 (6.4) 1 (1.4) 15 (8.2) 3 (6.7) 0.106 Environmental/Seasonal age at onset mean (SD) 6.9 (3.4) 9.0 (NA) 6.8 (3.8) 7.0 (1.0) 0.356 Medication Allergy 6 (2.0) 3 (4.2) 3 (1.6) 0 0.356 Medication Allergy age at onset mean (SD) 10.5 (4.2) 11.3 (5.0) 9.7 (4.0) NA (NA) 0.678 Eczema 143 (48.0) 23 (32.4) 97 (53.3) 23 (51.1) 0.008*** Reactive Airway Disease 5 (1.7) 0 4 (2.2) 1 (2.2) 0.555 Ottitis Media 36 (21.1) 11 (1.1) 7 (3.8) 0 0.208* Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392* Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764*	•					
Food Allergy onset mean age (SD) 5.8 (4.0) 3.8 (2.7) 6.5 (4.1) 4.6 (3.8) 0.0894 Environmental/Seasonal Allergies 19 (6.4) 1 (1.4) 15 (8.2) 3 (6.7) 0.106 Environmental/Seasonal age at onset mean (SD) 6.9 (3.4) 9.0 (NA) 6.8 (3.8) 7.0 (1.0) 0.838 Medication Allergy age at onset mean (SD) 10.5 (4.2) 11.3 (5.0) 9.7 (4.0) NA (NA) 0.678 Eczema 143 (48.0) 23 (32.4) 97 (53.3) 23 (51.1) 0.008***. Reactive Airway Disease 5 (1.7) 0 4 (2.2) 1 (2.2) 0.555 Ottiss Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.555 Ottiss Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.555 Ottiss Media 8 (27.7) 1 (1.4) 7 (3.8) 0 0.208 Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.294 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764	•			• •		
Environmental/Seasonal Allergies 19 (64) 1 (1.4) 15 (8.2) 3 (6.7) 0.106 Environmental/Seasonal age at onset mean (SD) 6.9 (3.4) 9.0 (NA) 6.8 (3.8) 7.0 (1.0) 0.838 Medication Allergy 6 (2.0) 3 (4.2) 3 (1.6) 0 0.356 Medication Allergy age at onset mean (SD) 10.5 (4.2) 11.3 (5.0) 9.7 (4.0) NA (NA) 0.68** Eczema 143 (48.0) 23 (32.4) 97 (53.3) 23 (51.1) 0.008*** Reactive Airway Disease 5 (1.7) 0 4 (2.2) 1 (2.2) 0.555 Ottitis Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.363 Bronchiolitis 38 (12.8) 6 (8.5) 23 (12.6) 9 (20.0) 0.208 Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.76 Delayed dental eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328	Food/Formula Allergies	58 (19.5)	10 (14.1)	39 (21.4)	9 (20.0)	0.428
Environmental/Seasonal age at onset mean (SD) 6.9 (3.4) 9.0 (NA) 6.8 (3.8) 7.0 (1.0) 0.838 Medication Allergy 6 (2.0) 3 (4.2) 3 (1.6) 0 0.356 Medication Allergy age at onset mean (SD) 10.5 (4.2) 11.3 (5.0) 9.7 (4.0) NA (NA) 0.678 Eczema 143 (48.0) 23 (32.4) 97 (53.3) 23 (51.1) 0.008**45 Reactive Airway Disease 5 (1.7) 0 4 (2.2) 1 (2.2) 0.555 Ottitis Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.363 Bronchiolitis 38 (12.8) 6 (8.5) 23 (12.6) 9 (20.0) 0.208 Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764 Delayed dental eruption age mean (SD) 4 (5.6) 11 (6.0) 0 0 0.244 1st Dental eruption age mean (SD) 8.0 (2.3) 8 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 C	Food Allergy onset mean age (SD)	5.8 (4.0)	3.8 (2.7)	6.5 (4.1)	4.6 (3.8)	0.089^{4}
Medication Allergy 6 (2.0) 3 (4.2) 3 (1.6) 0 0.356 Medication Allergy age at onset mean (SD) 10.5 (4.2) 11.3 (5.0) 9.7 (4.0) NA (NA) 0.678 Eczema 143 (48.0) 23 (32.4) 97 (53.3) 23 (51.1) 0.008*4.5 Reactive Airway Disease 5 (1.7) 0 4 (2.2) 1 (2.2) 0.555 Ottitis Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.363 Bronchiolitis 38 (12.8) 6 (8.5) 23 (12.6) 9 (20.0) 0.208 Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764 Delayed dental eruption 1 15 (5.0) 4 (5.6) 11 (6.0) 0 0.244 1 sental eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 Gastroesophageal Reflux Disease 89 (29.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.57 Eosinophilic esophag	Environmental/Seasonal Allergies	19 (6.4)	1 (1.4)	15 (8.2)	3 (6.7)	0.106
Medication Allergy age at onset mean (SD) 10.5 (4.2) 11.3 (5.0) 9.7 (4.0) NA (NA) 0.678 Eczema 143 (48.0) 23 (32.4) 97 (53.3) 23 (51.1) 0.008*4.5 Reactive Airway Disease 5 (1.7) 0 4 (2.2) 1 (2.2) 0.555 Ottiis Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.363 Bronchiolitis 38 (12.8) 6 (8.5) 23 (12.6) 9 (20.0) 0.208 Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764 1 ** Dental eruption* 15 (5.0) 4 (5.6) 11 (6.0) 0 0.244 1 ** Dental eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 Gastroesophageal Reflux Disease 89 (29.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.153 Constipation 10 (33.9) 3 (45.1) 0 0 0 0.361 Fall trains	Environmental/Seasonal age at onset mean (SD)	6.9 (3.4)	9.0 (NA)	6.8 (3.8)	7.0 (1.0)	0.838
Eczema 143 (48.0) 23 (32.4) 97 (53.3) 23 (51.1) 0.008*45 Reactive Airway Disease 5 (1.7) 0 4 (2.2) 1 (2.2) 0.555 Ottitis Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.363 Bronchiolitis 38 (12.8) 6 (8.5) 23 (12.6) 9 (20.0) 0.208 Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764 Delayed dental eruption 1 18 (13.7) 15 (5.0) 4 (5.6) 11 (6.0) 0 0.244 18 Obratial eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 Gastroesophageal Reflux Disease 89 (29.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.153 Constipation 101 (33.9) 32 (45.1) 56 (30.8) 13 (28.9) 0.0775 Essinophilic esophagitis 1 (0.3) 1 (1.4) 0 0 0.361 Fillure to Thrive (FTT)²	Medication Allergy	6 (2.0)	3 (4.2)	3 (1.6)	0	0.356
Reactive Airway Disease 5 (1.7) 0 4 (2.2) 1 (2.2) 0.555 Ottitis Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.363 Bronchiolitis 38 (12.8) 6 (8.5) 23 (12.6) 9 (20.0) 0.208 Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764 Delayed dental eruption¹ 15 (5.0) 4 (5.6) 11 (6.0) 0 0.244 1st Dental eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 Gastroesophageal Reflux Disease 89 (29.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.153 Constipation 101 (33.9) 32 (45.1) 56 (30.8) 13 (28.9) 0.075 Estimate to Thrive (FTT)² 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.073 FTT age at diagnosis mean (SD) 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus <td< td=""><td>Medication Allergy age at onset mean (SD)</td><td>10.5 (4.2)</td><td>11.3 (5.0)</td><td>9.7 (4.0)</td><td>NA (NA)</td><td>0.678</td></td<>	Medication Allergy age at onset mean (SD)	10.5 (4.2)	11.3 (5.0)	9.7 (4.0)	NA (NA)	0.678
Otitis Media 63 (21.1) 11 (15.5) 42 (23.1) 10 (22.2) 0.363 Bronchiolitis 38 (12.8) 6 (8.5) 23 (12.6) 9 (20.0) 0.208 Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764 Delayed dental eruption¹ 15 (5.0) 4 (5.6) 11 (6.0) 0 0.244 1s¹ Dental eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 Gastroesophageal Reflux Disease 89 (2.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.153 Constipation 101 (33.9) 32 (45.1) 8.0 (2.2) 7.7 (2.7) 0.328 Eosinophilic esophagitis 10 (13.3) 1 (1.4) 0 0 0.361 Fillure to Thrive (FTT)² 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.073⁵ Fird age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Strabismus<	Eczema	143 (48.0)	23 (32.4)	97 (53.3)	23 (51.1)	$0.008^{*4,5}$
Bronchiolitis 38 (12.8) 6 (8.5) 23 (12.6) 9 (20.0) 0.208 Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764 Delayed dental eruption 1 or 1	Reactive Airway Disease	5 (1.7)	0	4 (2.2)	1 (2.2)	0.555
Pneumonia 8 (2.7) 1 (1.4) 7 (3.8) 0 0.392 Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764 Delayed dental eruption¹ 15 (5.0) 4 (5.6) 11 (6.0) 0 0.244 1** Dental eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 Gastroesophageal Reflux Disease 89 (29.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.153 Constipation 101 (33.9) 32 (45.1) 56 (30.8) 13 (28.9) 0.0775 Eosinophilic esophagitis 1 (0.3) 1 (1.4) 0 0 0.361 Failure to Thrive (FTT)² 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.0735 FTT age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1	Otitis Media	63 (21.1)	11 (15.5)	42 (23.1)	10 (22.2)	0.363
Croup 11 (3.7) 2 (2.8) 8 (4.4) 1 (2.2) 0.764 Delayed dental eruption¹ 15 (5.0) 4 (5.6) 11 (6.0) 0 0.244 1st Dental eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 Gastroesophageal Reflux Disease 89 (29.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.153 Constipation 101 (33.9) 32 (45.1) 56 (30.8) 13 (28.9) 0.0775 Eosinophilic esophagitis 1 (0.3) 1 (1.4) 0 0 0.361 Failure to Thrive (FTT)² 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.0735 FTT age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0	Bronchiolitis	38 (12.8)	6 (8.5)	23 (12.6)	9 (20.0)	0.208
Delayed dental eruption¹ 15 (5.0) 4 (5.6) 11 (6.0) 0 0.244 1st Dental eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 Gastroesophageal Reflux Disease 89 (29.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.153 Constipation 101 (33.9) 32 (45.1) 56 (30.8) 13 (28.9) 0.0775 Eosinophilic esophagitis 1 (0.3) 1 (1.4) 0 0 0.361 Failure to Thrive (FTT)² 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.0735 FTT age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 10	Pneumonia	8 (2.7)	1 (1.4)	7 (3.8)	0	0.392
1st Dental eruption age mean (SD) 8.0 (2.3) 8.4 (2.1) 8.0 (2.2) 7.7 (2.7) 0.328 Gastroesophageal Reflux Disease 89 (29.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.153 Constipation 101 (33.9) 32 (45.1) 56 (30.8) 13 (28.9) 0.0775 Eosinophilic esophagitis 1 (0.3) 1 (1.4) 0 0 0.361 Failure to Thrive (FTT)² 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.0735 FTT age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Croup	11 (3.7)	2 (2.8)	8 (4.4)	1 (2.2)	0.764
Gastroesophageal Reflux Disease 89 (29.9) 17 (23.9) 62 (34.1) 10 (22.2) 0.153 Constipation 101 (33.9) 32 (45.1) 56 (30.8) 13 (28.9) 0.0775 Eosinophilic esophagitis 1 (0.3) 1 (1.4) 0 0 0.361 Failure to Thrive (FTT)² 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.0735 FTT age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Delayed dental eruption ¹	15 (5.0)	4 (5.6)	11 (6.0)	0	0.244
Constipation 101 (33.9) 32 (45.1) 56 (30.8) 13 (28.9) 0.0775 Eosinophilic esophagitis 1 (0.3) 1 (1.4) 0 0 0.361 Failure to Thrive (FTT)2 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.0735 FTT age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	1st Dental eruption age mean (SD)	8.0 (2.3)	8.4 (2.1)	8.0 (2.2)	7.7 (2.7)	0.328
Eosinophilic esophagitis 1 (0.3) 1 (1.4) 0 0 0.361 Failure to Thrive (FTT)² 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.0735 FTT age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Gastroesophageal Reflux Disease	89 (29.9)	17 (23.9)	62 (34.1)	10 (22.2)	0.153
Failure to Thrive (FTT)² 54 (18.1) 19 (26.8) 30 (16.5) 5 (11.1) 0.0735 FTT age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Constipation	101 (33.9)	32 (45.1)	56 (30.8)	13 (28.9)	0.077^{5}
FTT age at diagnosis mean (SD) 2.9 (3.7) 3.0 (4.1) 2.9 (3.7) 2.6 (2.4) 0.981 Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Eosinophilic esophagitis	1 (0.3)	1 (1.4)	0	0	0.361
Hearing Loss 4 (1.3) 0 4 (2.2) 0 0.481 Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Failure to Thrive (FTT) ²	54 (18.1)	19 (26.8)	30 (16.5)	5 (11.1)	0.073^{5}
Strabismus 71 (23.8) 14 (19.7) 45 (24.7) 12 (26.7) 0.610 Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	FTT age at diagnosis mean (SD)	2.9 (3.7)	3.0 (4.1)	2.9 (3.7)	2.6 (2.4)	0.981
Cleft Palate 1 (0.3) 0 1 (0.5) 0 1.000 Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Hearing Loss	4 (1.3)	0	4 (2.2)	0	0.481
Polydactyly 3 (1.0) 0 2 (1.1) 1 (2.2) 0.766 Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Strabismus	71 (23.8)	14 (19.7)	45 (24.7)	12 (26.7)	0.610
Clubfoot 1 (0.3) 1 (1.4) 0 0 0.380 Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Cleft Palate	1 (0.3)	0	1 (0.5)	0	1.000
Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Polydactyly	3 (1.0)	0	2 (1.1)	1 (2.2)	0.766
Torticollis 88 (29.5) 19 (26.8) 56 (30.8) 13 (28.9) 0.855	Clubfoot		1 (1.4)			0.380
	Torticollis	• •	• •	56 (30.8)	13 (28.9)	0.855
	Plagiocephaly					0.655

ANOVA or

	Overall	XXX	XXY	XYY	Fisher's Exact p-value
Velopharyngeal Insufficiency	2 (0.7)	0	2 (1.1)	0	1.000
Cardiac ASD or VSD – entire group	23 (7.7)	11 (15.5)	9 (4.9)	3 (6.7)	0.021*4,5
Cardiac ASD or VSD – echo subset (n=109) ⁶	23 (21.1)	11 (23.9)	9 (19.6)	3 (17.6)	0.858
Other cardiac finding ⁷ – entire group	31 (10.4)	11 (15.5)	16 (8.8)	4 (8.9)	0.280
Inguinal Hernia	3 (1.0)	0 (0)	2 (1.1)	1 (2.2)	0.517
Congenital Hip Dislocation / Dysplasia	4 (1.4)	1 (1.5)	1 (0.5)	2 (5.1)	0.098
Renal malformation – entire group	13 (4.4)	9 (12.7)	3 (1.6)	1 (2.2)	$0.003^{*4,5}$
Renal malformation – renal ultrasound subset (n=78)8	13 (16.7)	9 (16.1)	3 (23.1)	1 (11.1)	0.790
Umbilical Hernia	39 (13.1)	8 (11.3)	23 (12.6)	8 (17.8)	0.505
Hypotonia	116 (38.9)	27 (38.0)	72 (39.6)	17 (37.8)	0.985
Febrile Seizure	1 (0.3)	0	1 (0.5)	0	1.000
GU anomaly (% males; n=227)	21 (9.3)	NA	19 (10.4)	2 (4.4)	0.265
Hypospadias ⁹	3 (1.3)	NA	2 (1.2)	1 (2.2)	1.000
Penile chordee or webbing	12 (5.3)	NA	11 (6.0)	1 (2.2)	0.468
Hydrocele	16 (7.0)	NA	15 (8.2)	1 (2.2)	0.206
Cryptorchidism	12 (5.3)	NA	11 (6.0)	1 (2.2)	0.468
Any hospitalization (excludes NICU)	37 (12.4)	7 (9.9)	22 (12.1)	8 (17.8)	0.459
Hospitalization for respiratory infection	22 (7.4)	5 (7.0)	13 (7.1)	4 (8.9)	0.905
Age (months) of first hospitalization	5.9 (4.0)	4.4 (4.7)	7.8 (3.6)	4.8 (3.7)	0.292
Any surgery (one or more surgeries)	32 (10.7)	6 (8.5)	18 (9.9)	8 (17.8)	0.240
Ear PE tubes	7 (2.3)	1 (1.4)	5 (2.7)	1 (2.2)	1.000
Tonsillectomy / Adenoidectomy	2 (0.7)	0	2 (1.1)	0	1.000
GU surgery (excludes circumcision) ¹⁰	10 (3.4)	1 (1.4)	6 (3.3)	3 (6.7)	0.325
Other surgery ¹¹	13 (4.4)	3 (4.2)	6 (3.3)	4 (8.9)	0.232
Age (months) of first surgery	8.2 (3.5)	10.6 (1.6)	8.8 (3.1)	6.0 (4.1)	0.103^{3}
Frenotomy (frenulectomy) procedure ¹²	38 (12.8)	2 (2.8)	23 (12.6)	13 (28.9)	<0.001*3,5

ANOVA or

Participants who have completed their 12-month study visit are included. Categorical data are represented as n (%), and continuous data are mean (standard deviation). All ages are in months. *p<0.05

1 Delayed dental eruption defined as lack of eruption by 12 months of age
2 Failure to Thrive defined as medical evaluation and intervention required due to inadequate weight gain, also called growth faltering or inadequate weight

gain

³ Pairwise comparisons analysis: XXY, XXX ≠ XYY

Overall

XXX

XXY

XYY

4 Pairwise comparisons analysis: XXY ≠ XXX, XYY

5 Pairwise comparisons analysis: XXX ≠ XXY, XYY

6 Echocardiogram group total n=109 (46 XXX, 46 XXY, 17 XYY)

7 Other cardiac findings included (some participants had more than 1 finding): Patent Ductus Arteriosus (n=4), Pulmonic stenosis (n=5), Situs inversus (n=1), Patent Foramen Ovale (n=13), Double aortic arch & vascular ring, repair required (n=1), Right aortic arch (n=1), Bicuspid aortic valve (n=1) 8 Renal ultrasound group total n=61 (43 XXX, 11 XXY, 7 XYY). Renal ultrasound findings included: Hydronephrosis (n=5), Pelvic caliectasis (n=6), Bilateral small kidneys (n=2), Duplicated collecting system (n=1), Nephrocalcinosis (n=1) (1 participant had both duplicated collecting system and hydronephrosis, 1 participant had both hydronephrosis and pelvic caliectasis)

- 9 All cases of hypospadias classified as subcoronal hypospadias, no surgical intervention indicated
- 10 GU surgical repairs include: Hidden penis (n=3), penile webbing / chordee (n=6), Bifid scrotum(n=1), ear tag(n=1), ureterocele-ectomy (n=1), some participants had >1 finding
- 11 Other surgeries included: anoplasty (n=1), dermoid cyst removal (n=2), ear tag or accessory digit removal (n=4), g-tube placement (n=1), hip dislocation repair (n=1), supraglottoplasty (n=2), tenotomy (n=1), vascular ring repair (n=1)
- 12 Frenotomy not included as surgery

Table 4 Physical Examination Growth z-scores at 2, 6, and 12 months¹

	Overall	XXX	XXY	XYY	ANOVA or Fisher's Exact p- value
2-month Physical Exam Subset	135	20	108	7	
Weight z-score mean (SD)	-0.7 (1.1)	-0.79 (1.0)	-0.76 (1.0)	0.35 (1.7)	0.023*2
Length z-score mean (SD)	-0.59 (1.2)	-0.51 (1.2)	-0.71 (1.1)	1.1 (1.6)	<0.001*2
Weight-for-Length z-score mean (SD)	-0.23 (1.1)	-0.43 (0.8)	-0.17 (1.1)	-0.53 (1.3)	0.487
Head circumference z-score mean (SD)	-0.12 (1.1)	-0.3 (0.9)	-0.17 (1.1)	1.1 (1.7)	0.008*2
Stretched Penile Length z-score (SD) (males only w/o history of testosterone, $n=110$; XXY = 103 , XYY = 7) ³	-0.23 (0.76)	NA	-0.29 (0.72)	0.73 (0.90)	<0.001*
Z-Score < -2.0	2 (1.5)	NA	2 (1.9)	0 (0)	1.000
6-month Physical Exam Subset	193	42	130	21	
Weight z-score mean (SD)	-0.11 (1.1)	-0.31 (1.0)	-0.11 (1.1)	0.39 (1.4)	0.114
Length z-score mean (SD)	-0.17 (1.2)	-0.34 (1.1)	-0.18 (1.2)	0.20 (1.6)	0.245
Weight-for-Length z-score mean (SD)	0.08 (1.1)	-0.04 (1.0)	0.08 (1.2)	0.40 (0.9)	0.335
Head circumference z-score mean (SD)	0.06 (1.2)	-0.05 (0.8)	-0.06 (1.2)	1.02 (1.4)	<0.001*2
Stretched Penile Length z-score (SD) (males only w/o history of testosterone, n=71; XXY = 50, XYY = 21) ³	0.15 (1.1)	NA	0.16 (1.1)	0.09 (1.0)	0.783
Z-Score < -2.0	2 (1.0)	NA	2 (1.5)	0 (0)	1.000
12-month Physical Exam Subset	255	55	164	36	
Weight z-score mean (SD)	0.27 (1.1)	-0.08 (0.8)	0.28 (1.1)	0.69 (1.2)	0.005*2,4
Length z-score mean (SD)	0.05 (1.2)	-0.39 (1.0)	0.07 (1.2)	0.60 (1.5)	0.001*2,4
Weight-for-Length z-score mean (SD)	0.35 (1.1)	0.15 (0.8)	0.36 (1.1)	0.60 (1.1)	0.184
Head circumference z-score mean (SD)	0.24 (1.1)	0.04 (1.0)	0.17 (1.1)	0.78 (1.2)	0.006*2
Stretched Penile Length z-score (SD) (males only w/o history of testosterone, n=100; XXY = 64, XYY = 36) ³	0.08 (1.1)	NA	0.08 (1.1)	0.08 (1.0)	0.994
Z-Score < -2.0	8 (3.6)	NA	7 (4.9)	1 (2.9)	0.253

¹ Total sample size receiving in person physical examination at each study visit is variable due to enrollment age and COVID-19 restrictions

² Pairwise comparisons analysis: XXY, XXX < XYY

³ In XXY, those previously treated with exogenous testosterone were excluded: 2-month n=5 (4.6%), 6-month n=80 (61.5%), 12-month n=100 (61.0%)

⁴ Pairwise comparisons analysis: XXX < XXY, XYY

TABLE 5: Medical Conditions at Higher Risk in Infants with Prenatal SCT Diagnosis and Guidance for Clinical Care

Feature	General	SCT Prevalence	Relative Risk	Considerations for Clinical Care
	Prevalence ^a	(95%CI)	in SCT	
Infant-related breastfeeding difficulties	19% ³⁹	51.7% (46-57.4%)	2.7 (2.1-3.4)	Encourage prenatal breastfeeding classes if parent wishes to breastfeed Proactive lactation consultation after delivery Breast pump for expressed breastmilk in case of delay with successful latch or ongoing breastfeeding challenges Targeted history in newborn nursery and first well child checks Evaluate for ankyloglossia and consider referral for further evaluation
Failure to Thrive / Growth Faltering	10% ⁴⁰	18.1% (13.7-22.5%)	1.8 (1.32.5)	Early feeding / breastfeeding support as above Close follow-up for growth / weight gain in first months of life Caloric supplementation and other medical work-up as indicated Consideration of feeding therapy by feeding specialist, speech, or occupational therapy
Constipation (requiring intervention)	7.0% 41,42	33.9% (28.5-39.3%)	5.2 (4.3-6.3)	Sorbitol-containing juices (eg, apple, prune, or pear) Lactulose, polyethylene glycol, glycerin suppositories under physician supervision; Referral to gastroenterology if needed
Any Allergies	10.4%	24.2% (19.3%-29%)	2.6 (2.1-3.2)	
Food / Formula Allergies	8.8% ⁴³	19.5% (15-24%)	2.4 (1.9-3.1)	Awareness of increased risk and consideration of allergic etiology for feeding, reflux, constipation, or colic concerns Parent education of milk protein and food allergy symptoms, staged introduction of new foods, indications for diphenhydramine administration, and when to seek emergent care
Eczema	13.7% 44	48.0% (42.3-53.7%)	3.5 (3.1-3.9)	Awareness of increased risk, targeted physical exam, standard pediatric eczema interventions
Positional Torticollis	3.9% ^{45,46}	28.2% (23.1-33.3%)	7.2 (5.1-10.2)	Targeted physical examination for identification Recommend tummy time, neck stretching exercises, and positioning Consider referral to physical therapy Consider referral for molding helmet if associated with plagiocephaly
Male genitourinary abnormalities Cryptorchidism (XXY only)^ Hypospadias Chordee Penis length z-score <-2.0	1.1% ⁴⁷ 0.4% ⁴⁸ 4.5% ⁴⁹ 2.5%	3.5% (1.4-5.6%) 1.3% (0-2.6%) 5.3% (2.7-7.8%) 3.5% (0.4-27.8%)	2.3 (1.1-4.6) 3.1 (1.0-9.6) 1.3 (0.75-2.3) 1.8 (0.38, 8.2)	Targeted physical examination for cryptorchidism, hypospadias, chordee, webbing, short phallus Referral to Pediatric Urology if abnormalities identified Consider infant testosterone therapy if stretched penile length < 2cm in term infant
Strabismus	2.4% ⁵⁰	6.7% (3.9-9.6%)	3.1 (2.0-4.8)	Targeted physical examination with awareness of possible pseudostrabismus related to epicanthal folds Referral to ophthalmology if present after 6 months of age
Cardiac septal defects	0.45% 51	7.7% (4.7-10.7%)	17.2 (11.6-25.4)	Targeted cardiac examination Echocardiogram and referral to cardiology if abnormal findings


Renal malformations	0.46% 52	4.4% (2-6.7%)	9.7 (5.16.5)	Renal ultrasound to evaluate for structural abnormalities
				Referral to pediatric nephrology and/or urology if structural defects found
Hypotonia	8% 53	32.9% (27.6-38.2%)	3.9 (3.0-5.1)	Close monitoring of motor development due to increased risk for delays
				Referral for physical therapy if associated with delays
				Further neurologic evaluation if severe or asymmetric
Other minor dysmorphologies				No clinical implications, reassurance to family
(epicanthal folds, increased				
intercanthal distance,				
clinodactyly, ear differences)				

^aEstimated general pediatric population based on cited literature references; SCT = sex chromosome trisomy ^XYY prevalence not different than the general population

FIGURE 1: Schematic of eXtraordinary Babies Study Visits



FIGURE 2: Participant US Regional Representation



Point Sizes range from N = 1 to N = 38. Hawaii and Alaska are both represented with N = 1. N = 9 patients are international.

FIGURE 3: Physical Features on Examination





FIGURE S1: Participant Growth Z-Score Trajectories



Caption: LOESS (locally estimated scatterplot smoothing) smoothed trajectories of growth parameter z-scores by trisomy condition